Sichuan Huaxin Pharmaceutical Co., Ltd.

Main purpose: The diclofenac sodium sustained-release tablets (trade name: Voltaren® Retard, specification: 100 mg) produced by Novartis Pharma Schweiz AG were used as the reference preparation, and the diclofenac sodium sustained-release tablets (specification: 0.1 g) produced by Sichuan Huaxin Pharmaceutical Co., Ltd. were used as the test preparation. Through a single-center, randomized, open, two-period, double-crossover clinical trial design, the absorption rate and degree of fasting and postprandial administration in healthy humans were compared to evaluate the bioequivalence of the two preparations. Secondary purpose: Evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Main purpose: The diclofenac sodium sustained-release tablets (trade name: Voltaren® Retard, specification: 100 mg) produced by Novartis Pharma Schweiz AG were used as the reference preparation, and the diclofenac sodium sustained-release tablets (specification: 0.1 g) produced by Sichuan Huaxin Pharmaceutical Co., Ltd. were used as the test preparation. Through a single-center, randomized, open, double-period, double-crossover clinical trial design, the absorption rate and degree of single oral administration under fasting and postprandial conditions in healthy humans were compared to evaluate the bioequivalence of the two preparations in humans. Secondary purpose: Observe and evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects.